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ttp://dx.doi.org/10.1016/j.ajpath.2013.01.006miRNAs are small noncoding RNAs with critical roles in a large variety of biological processes such as
development and tumorigenesis. miRNA expression proﬁling has been reported to be a powerful tool to
classify tissue samples, including cancers, based on their developmental lineage. In this study, we have
proﬁled the expression of miRNAs in bladder carcinoma in situ (CIS) and distinct cell compartments of
the normal bladder, namely umbrella and basal-intermediate urothelial cells, as well as the muscularis
propria. We identiﬁed several miRNAs differentially expressed between umbrella and basal-intermediate
cells (miR-133a, miR-139-3p, miR-142-3p, miR-199b-5p, and miR-221). In situ hybridization conﬁrmed
the expression of miR-133a and miR-139-3p in umbrella cells, and miR-142-3p in basal-intermediate
cells. Strikingly, miRNA expression levels of CIS most closely resembled the miRNA proﬁle of
umbrella cells. Finally, we examined well-established umbrella and basal-intermediate cell immuno-
histochemical biomarkers in an independent series of CIS samples. Again, this analysis revealed the
signiﬁcant expression of umbrella-speciﬁc markers in CIS when compared to non-CIS lesions. Overall,
our studies represent a comprehensive and accurate description of the different miRNAs expressed in
CIS tumors and three distinct histological areas of the urinary bladder. Notably, this study provides
evidence of the possible origin relationship between CIS and normal umbrella cells. (Am J Pathol 2013,
182: 1171e1179; http://dx.doi.org/10.1016/j.ajpath.2013.01.006)Supported in part by NIH grant P01 CA087497 (C.C.C.).The urothelium is composed of specialized epithelial cells
that coat the entire urinary tract, including the renal pelvis,
ureter, bladder, and female proximal urethra. In humans,
the urothelium of the bladder is a stratiﬁed epithelium,
comprised of three different cell layers: i) basal, ii) inter-
mediate, and iii) superﬁcial umbrella cells. The basal
membrane separates the urothelium from the stroma of the
bladder, which includes the lamina propria and the muscu-
laris propria.
Umbrella (UM) cells are distinct from basal-intermediate
(B/i) cells in both morphology and expression of speciﬁc
biomarkers. UM cells express high levels of uroplakin II
(UPKII),1 lowmolecular weight cytokeratins (CKs; eg, CK18
and CK20),2 and Lewis X determinant,3 however, none of
these markers are expressed in B/i cells. In contrast, B/i cells
stain strongly for high molecular weight cytokeratinsstigative Pathology.
.(eg, CK5, CK10, CK14), p63,4 and mature A and B blood
group antigens, all of which are negative in umbrella (UM)
cells. Although it has been proposed that UM cells mature
from the underlying B/i cells in a manner similar to epithelial
development of the skin, the vast number of differences
between the two cell types suggests that UM cells may orig-
inate from a precursor distinct from B/i cells.5
The urothelium functions as a permeability barrier
between blood and urine and is constantly exposed to
potential carcinogens in urine. It is not surprising, therefore,
that 90% of bladder tumors originate from the urothelium.6
Bladder tumors are classiﬁed into two groups based on
phenotypic and molecular proﬁles. Low-grade tumors are
always papillary (ie, protruding into the lumen), and usually
Jia et alsuperﬁcial and nonmuscle invasive. In contrast, high-grade
tumors can be papillary or nonpapillary, such as carci-
noma in situ (CIS), and are often invasive. Nonmuscle
invasive bladder tumors (low-grade tumors and carcinoma
stages Ta, Tis, T1) comprise 75% to 85% of total bladder
cancer cases at initial presentation.6 CIS presents as a ﬂat
lesion, found in association with 75% to 90% of high-grade
papillary cases and in 45% to 65% of all invasive urothelial
tumors.7,8 Presence of CIS greatly increases the risk of
disease progression to invasive urothelial carcinoma; once
the tumor is metastatic, the median survival rate is
approximately 7 to 20 months.6,9 CIS is characterized by
aneuploidy, and its histological abnormalities include
enlarged nuclei and nucleoli and hyperchromasia.7 Given
the heterogeneity of bladder tumors, it is possible that the
two distinct populations of normal urothelium (ie, UM cells
and B/i cells) may have different implications in bladder
tumorigenesis. A better characterization of both normal
urothelium and bladder cancer cases is therefore needed to
delineate the role of these cells in tumorigenesis.
miRNAs have been implicated in development and
tumorigenesis, as reviewed in Zhang et al,10 and He and
Hannon,11 and Esquela-Kerscher and Slack.12 To date, more
than 21,000 distinct mature miRNA sequences have been
identiﬁed in 193 different species (miRBase 19) with more
than 2000 miRNAs identiﬁed in humans.13,14 Transcribed
from independent miRNA genes or as introns of protein-
coding mRNAs, miRNAs repress speciﬁc mRNA expres-
sion through 30-UTR base pairing.15 Furthermore, miRNA
proﬁles can classify tumors based on their respective devel-
opmental lineage.16 To the best of our knowledge, miRNA
proﬁles of UM and B/i cells have not been examined. More-
over, several groups have compared miRNA expression
between normal mucosa and bladder tumors,17e25 but none
has assessed miRNA expression in CIS samples relative to
subpopulations of normal urothelium.
For the study described herein, we used laser capture
microdissection to obtain UM and B/i cell populations from
normal bladder urothelium, aswell as pure CIS cells. Thenwe
proﬁled the expression of both miRNAs and mRNAs in CIS
tumors and three distinct histological areas of the urinary
bladder: i) the UM (lumen-facing cells), ii) the B/i cells,
and iii) the muscularis propria (MP; stromal). We identiﬁed
several miRNAs differentially expressed between UM and
B/i cells. Furthermore, and for the ﬁrst time, through miRNA
proﬁling and immunohistochemical analyses, we established
a correlation between CIS and UM cells.
Materials and Methods
Cell Culture
The immortalized normal urothelial cell line, Human Uro-
thelial Cell (HUC) from ScienCell Research Laboratories,
was grown in Urothelial Cell Medium (ScienCell Research
Laboratories, Carlsbad, CA) at 37C in a humidiﬁed air1172atmosphere at 5% CO2. RNA was extracted from the cells
using the miRVANA Kit (Ambion, Carlsbad, CA).
Laser Capture Microdissection of Normal Bladder
Urothelium and CIS Biopsies
Human normal (nZ 3) and tumor bladder (CIS, nZ 4) tissue
samples were obtained through approved protocols of the
International Review Board. The three normal bladders were
obtained from organ donors (males: ages 15, 25, and 28 years
old) with no history of bladder cancer through the International
Institute for the Advancement of Medicine. Fresh tissues were
processed and frozen in optimal cutting temperature (OCT)
molds, which were used for laser capture microdissection. CIS
samples were obtained from patients who had undergone
radical cystectomy for an invasive urothelial carcinoma and
sections that did not include the invasive area were chosen for
further processing. Frozen normal bladder urothelium was
microdissected to obtain pure populations ofUMcells,B/i cells,
andMP. FrozenCIS sampleswere alsomicrodissected from the
bladder tissue samples to obtain pure populations of tumor cells.
To rule out the possibility of normal urothelial cell contamina-
tion in CIS samples, only cases in which the CIS lesion
permeated the whole thickness of the epithelium were chosen.
Cases in which we could histologically identify UM or B/i cells
surrounding the malignant cells by H&E stain, and cases with
pagetoid spread or denuded CIS were not used. Brieﬂy, 20-mm
sections from OCT blocks were cut and mounted on Mem-
braneSlide NF 1.0 PEN (Zeiss, Munich, Germany) and stored
at 80C until use. Slides were ﬁxed in ethanol at 20C for
2 minutes, washed in diethyl-pyrocarbonate-H2O, stained with
hematoxylin for 1 minute, washed in diethyl-pyrocarbonate-
H2O, and air-dried. PALM Microbeam IV Laser Capture
Microscope (Zeiss) was used to perform laser microdissection.
A total of 2520-mmsectionswereprepared fromeachsample, in
which the microdissected tissue was pooled per patient to
extract RNA. Formalin-ﬁxed parafﬁn-embedded (FFPE) CIS
samples (nZ 6) were macrodissected by scratching 40 10-mm
sections in which dissected tissue was pooled per patient.
RNA Extraction and Microarray Proﬁling and Data
Analysis
RNA was extracted from microdissected samples using
RNAquesous-Micro Kit (Ambion). RNA was extracted
using RecoverAll Total Nucleic Acid Isolation Kit for FFPE
(Ambion) for macrodissected samples. The quality of all
RNA samples was veriﬁed using a RNA Pico Kit (Agilent,
Santa Clara, CA). Only sample qualities with RNA Integrity
Number >6.0 and with clean 18S and 28S peaks were used,
as previously described.26
Agilent Human miRNA Microarray (V3, based on Sanger
miRbase release 12.0) were used for measuring miRNA
expression in bladder samples. Samples used for the Agilent
miRNA microarray were labeled as described by the
manufacturer.ajp.amjpathol.org - The American Journal of Pathology
Common miR Signature between CIS and UMAffymetrix HumanU133 Plus 2.0 (Santa Clara, CA) arrays
were used for measuring gene expression in bladder samples.
Samples used forAffymetrixmicroarraywere ampliﬁed using
the Ovation RNAAmpliﬁcation System (NuGen, San Carlos,
CA) and labeled using FL-Ovation cDNA Biotin Module V2
(NuGen) according to the manufacturer’s protocol. Raw
intensity miRNA data were normalized and median trans-
formed using GeneSpring GX 12 (Agilent). The raw mRNA
data were log transformed and analyzed using Partek Geno-
mics Suite 6.6 (Partek, Saint Louis, MO). Only detected
probesets were used, and compromised or undetected pro-
besets were ﬁltered out. One-way analysis of variance and
Tukey’s honestly signiﬁcant difference post hoc test were
performed across all samples to obtain miRNAs or mRNAs
differentially expressed (P < 0.05). Unsupervised hierar-
chical cluster analysis was performed on the list of differen-
tially expressed probesets with a fold change 2 (295
miRNAs, 1113 mRNAs).Quantitative Real-Time RT-PCR miRNA Expression
Proﬁling
TaqMan microRNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA) was used to convert miRNA to
cDNA. Forty-fourenucleotide (nt) reverse transcription
primers were designed so that the ﬁrst 36 nt formed an internal
stem loop and the last 8 nt were complementary to the mature
miRNA sequence of interest. Qiagen Reverse Transcriptase
System (Qiagen, Valencia, CA) was used to produce cDNA
from mRNA. Qiagen QuantiTect PCR (Qiagen) was used to
measure quantitative expression of miRNA andmRNA. PCR
assays were performed as described by the manufacturer
using a Stratagene MX3005P PCR system (Agilent). For
normalization, we used RNU6B or ACTIN for miRNA and
mRNA, respectively.Immunohistochemical Detection of Biomarkers
Immunohistochemical analyses were conducted on FFPE
tissue sections from 10 cases of normal human bladder and
19 CIS specimens according to the standard avidin-biotin
protocol. These 10 cases of normal bladder included the three
cases used for the laser microdissection (organ donors) and
seven cases of histologically normal urothelium obtained from
patients who had undergone a radical cystectomy for anTable 1 Sequence of the Sense-Strand of the Primary Transcript of m
Probe sequence
50-GGGCAGTCAACGACATTTTTCTCCATTAATCCCAAAGTCAGTGTAA
AAAACAAGATGGAATGTAGAGATACTTGATTGTCGCAATTTAGGGAA
TTTTTTTTTACCATGACATAGTGTATTTGTTACCACTGGATCTCAGT
AATCTTATTAAATACTCTGCACATTTTATTAACTAATAAATAGGACA
GAAAAACCGACTTAATTTGTAAGTGTAACAAGATACTTACAGTTGGA
This probe was 30 digoxigenin-labeled and used as a negative control in miRN
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sponded to biopsies of patients with primary CIS and the other
ninewereobtained fromcystectomyspecimens ofpatientswith
a diagnosis of invasive bladder cancer. Brieﬂy, 5-mm sections
were deparafﬁnized and submitted to antigen retrieval by
steamer treatment for 15minutes in 10mmol/L citrate buffer at
pH 6.0. Subsequently, slides were incubated in 10% normal
serum for 30minutes, followedbyprimary antibody incubation
overnight at 4C. Primary antibodies used were anti-UPKII
goat polyclonal (Santa Cruz Biotechnology, Dallas, TX), anti-
CK5 rabbit polyclonal (AF138, Covance, Princeton, NJ), anti-
CK20 mouse monoclonal (clone Ks20.8, Dako, Carpinteria,
CA), and anti-high molecular weight cytokeratin mouse
monoclonal (clone 34bE12,Dako).Then slideswere incubated
with biotinylated immunoglobulins at 1:500 dilution for 30
minutes (Vector Laboratories, Inc., Burlingame, CA) followed
by avidin-biotin peroxidase complexes at a 1:25 dilution
(Vector Laboratories, Inc.) for 30 minutes. Diaminobenzidine
was used as chromogen and hematoxylin as the nuclear coun-
terstain. Slides were analyzed with a Nikon Eclipse 50i micro-
scope (Nikon Instruments,Melville,NY) equippedwith aSPOT
Insight2MP Mosaic camera and SPOT Advanced software
version 5.0 (Diagnostic Instruments, Sterling Heights, MI).In Situ Detection of miRNAs
In situ detection of miRNAs was performed on 10-mm frozen
tissue sections from normal human bladders obtained from
healthy donor patients (n Z 3) and B6-wt mouse bladders
(n Z 15). Sections were ﬁxed in 4% paraformaldehyde,
acetylated, and prehybridized in hybridization solution
(50% formamide, 5 saline-sodium citrate, 0.5 mg/mL yeast
tRNA, 1X Denhardt’s solution) for 3 hours at 25C below the
predicted Tm of the probe. Five pmol probe (LNA-modiﬁed
and FITC-labeled oligonucleotide; Exiqon, Woburn, MA)
complementary toU6 (positive control),miR-133a,miR-139-
3p, and miR-142-3p was hybridized to the sections overnight
in a humidiﬁed chamber at prehybridization temperature.
Posthybridization slides were washed with 5 and 0.2
saline-sodium citrate, blocked in 10% normal goat serum for
30 minutes, and incubated in anti-ﬂuorescein isothiocyanate/
alkaline-phosphatase antibody (Vector Laboratories, Inc.) at
1:400 at 4Covernight. Five pmol sense-strand of the primary
transcript of the miR-424/503 cluster (Table 1) was used as
negative control. In situ hybridization signals were detectediR-424/503 Cluster
Hybridization temperature
AAGTTGTTTGTAAATATCATTGCC-
TGGGGTTATTGTTACTAATGACTT-
CTGGATGTTATAAATTCGATACTT-
CTTAACATTCATTGTACTGGTTTT-
TAATTT-30
65C
A ISH stainings.
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counterstained with Nuclear Fast Red (Sigma-Aldrich, St.
Louis, MO), mounted using 80% glycerol, and analyzed with
a Nikon Eclipse 50i microscope (Nikon Instruments) equip-
ped with a SPOT Insight2MP Mosaic camera and SPOT
Advanced software version 5.0 (Diagnostic Instruments,
Sterling Heights, MI).
Results
Isolation of Pure Populations of UM, B/i, and MP by
Laser Capture Microdissection
As previously described,5,27 UPKII and CK5were shown to be
differentially expressed in UM versus B/i cells in normal
bladder urothelium (Figure 1A). Membranous expression of
UPKII was observed exclusively in the UM layer, whereas
cytoplasmic CK5 expressionwas speciﬁc for the cells in the B/i
layers. Three cases of normal bladder samples and four CIS
lesions were used to perform the study (Figure 1B). The uro-
thelium was microdissected to separate UM from B/i cells as
explained in Material and Methods (Figure 1C). The MP
population was obtained by removing the urothelium and
lamina propria throughmacrodissection. Quantitative real-time
RT-PCR (RT-qPCR) showed on average an eightfold decrease
in UPKII levels in B/i versus UM, and a twofold increase in
CK5 inB/i versusUM (Figure 1D). These results demonstrated
that the distinct urothelial subpopulations could be efﬁciently
separated by microdissection.1174miRNA Microarray Proﬁling Associates CIS with
Umbrella Cells
Once we had isolated pure populations of urothelial subtypes
and stroma, we examined themiRNA expression in these cells,
along with four CIS cases and an HUC line. Of the 984 human
miRNAs evaluated, there were 295 miRNAs differentially
expressed (fold change 2) across the normal bladder, HUC
line, and CIS. Interestingly, hierarchical cluster analysis of
these 295 miRNAs separated samples were based on cell type
of origin instead of normal versus cancer. Endoderm-derived
cells, including the urothelium, CIS, and HUC, clustered into
one arm,whereasmesoderm-derivedMPbranched into another
arm (Supplemental Figure S1). Expression of individual
samples was averaged into groups, with the exception of the
HUC line. Notably, the level of expression of miRNAs in CIS
most closely resembled the level observed in normal UM cells,
whereas the HUC line shared greater similarity in miRNA
expressionwithB/i cells. So far, ananalysis of a broad sampling
of miRNAs indicates a correlation between UM and CIS cells.
Then we focused our analyses on the individual miRNA
and mRNA proﬁles of UM, B/I, and CIS, because MP is not
epithelial in origin and HUC is a cell line. With the removal
of MP and HUC, there were 41 miRNAs and 1113 mRNAs
differentially expressed across UM, B/i, and CIS samples. A
hierarchical cluster analysis of individual cases revealed
distinct miRNA expression proﬁles between UM cells and
B/i cells; interestingly, the majority of CIS samples clus-
tered with UM cells (Figure 2A). From these 41 miRNAs,Figure 1 Experimental design and isolation of
UM and B/i cells from normal bladder urothelium. A:
Representative immunohistochemical analyses of
UPKII and CK5 in normal urothelium; prominent UM
cells (arrows). Scale barZ 50 mm. B: Microphoto-
graph of frozen tissue section was taken with PALM
Microbeam IV Laser Capture Microscope (LCM; Zeiss).
UM, B/i, and CIS samples were microdissected and
analyzedwith bothmiRNA andmRNAmicroarrays.MP
samples weremacrodissected (MD) and analyzedonly
in the miRNA microarray. C: Delineation of UM cells,
before and after laser capture. Scale barZ 75 mm.D:
RT-qPCR onUM and B/i cells for UPKII and CK5. Graph
shows B/i log2 fold expression; B/i expression
normalized to UM. Horizontal line indicates the
sample median. Square indicates the sample mean.
*P < 0.05 by Student’s t-test.
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Figure 2 Hierarchical clustering of normal urothelium and CIS. A: Samples are in columns and miRNAs are in rows. Individual samples of normal urothelium
and CIS were clustered according to the expression signature of 41 differentially expressed miRNAs (P  0.05). B: Samples are in columns, mRNAs are in rows.
Normal urothelium and CIS samples were clustered according to the expression signature of 1113 differentially expressed mRNAs (P  0.05). C: Venn diagram
illustrating 698 mRNAs upregulated in common between CIS compared to normal UM and B/i cells. There were 753 mRNAs upregulated in CIS compared to B/i
cells, and 738 mRNAs upregulated in CIS compared to UM cells. Arbitrary assignment of cluster groups is as follows: A, UM cells; B, B/i cells; C, CIS.
Common miR Signature between CIS and UMfour (ie, let-7b*, miR-1281, miR-133a, and miR-139-3p)
exhibited higher levels of expression in both CIS and UM
cells when compared to B/i cells. Conversely, nine miRNAs
(ie, miR-142-3p, miR-199b-5p, miR-200a, miR-200b,
miR-205, miR-21, miR-27b, miR-424, and miR-491-3p)
displayed higher levels of expression in B/i cells than CIS
and UM cells. Importantly, only ﬁve of 41 miRNAs were
signiﬁcantly altered between UM and B/i cells (Table 2).
In contrast, based on mRNA expression levels, normal
urothelium (UM and B/i) and CIS formed two separate arms
(Figure 2B). From the 1113 mRNAs differently expressed,
23 were commonly down-regulated in UM cells and CIS in
comparison to B/i cells, whereas another 23 followed the
opposite trend (Supplemental Table S1). Notably, TP63
(speciﬁc to B/i cells, but absent in UM cells) was down-
regulated in UM cells and CIS compared to B/i cells.
Interestingly, among the genes that were upregulated in UM
cells and CIS compared to B/i cells, we found CD24,
a proposed marker of tumor-initiating cells (reviewed by
Gires28), and genes involved in metabolism, such as
GFOD2, NDUFB2, and NQO1.
In fact, more than half of the differentially expressed
mRNAs (698) were upregulated in CIS compared to UM and
B/i samples (Figure 2C). Gene ontology enrichment was
performed on the 698 mRNAs to investigate biologically
driven effects. This analysis revealed 74 biological processesTable 2 Statistical Results and Location of a Set of miRNAs Signiﬁcant
Urothelium
miRNA Chromosome Fold change (UM vs B/i)
hsa-miR-139-3p 11q13.4 2.30
hsa-miR-199b-5p 9q34.11 4.03
hsa-miR-142-3p 2q35 3.12
hsa-miR-133a 18q11.2 2.26
hsa-miR-221 Xp11.3 5.04
ISH, in situ hybridization; ND, not detectable.
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top seven (P < 0.005) are involved in genomic alterations,
transcription regulation, and cell cycle (Supplemental Table
S2). Furthermore, we examined differentially expressed
pathways in the group of 698 mRNAs upregulated in CIS
using Pathway analysis of variance (Partek Genomics Suite
6.6). Statistically signiﬁcant pathways with more than 10
genes involved include metabolic pathways and pathways in
cancer (Supplemental Table S3). Not surprisingly, in this list
(Supplemental Table S4), the bladder cancer pathway was
enriched (enrichment score, 3.2). As supported by gene
ontology analysis, hierarchical clustering by global gene
expression separated samples based on normal (UM and B/i)
versus cancer (CIS).
Validation of miRNA Arrays in UM and B/i Cells
Having examined miRNA and mRNA proﬁles globally in
both normal urothelium and in CIS cases, we decided to
further explore the ﬁve miRNAs that were statistically
differentially expressed between UM cells and B/i cells
(Table 2), according to the microarray data. We performed
RT-qPCR to determine the expression of the mature form of
these ﬁve miRNAs (Figure 3A). RT-qPCR results showed
an average Pearson correlation to the microarray data of
0.95. The miR-133a and miR-139-3p were upregulated inly Differentially Expressed Between UM and B/i Cells in the Normal
P value RT-qPCR veriﬁcation ISH veriﬁcation
0.006 Yes Yes
0.024 Yes ND
0.030 Yes Yes
0.037 Yes Yes
0.048 Yes ND
1175
Figure 3 Validation of differentially expressed miRNAs from microarray
data. A: RT-qPCR on UM and B/i cells for various miRNAs. Graph shows B/i
log2 fold expression; B/i expression is normalized to UM. Horizontal line
indicates the sample median. Square indicates the sample mean. *P < 0.05
by Student’s t-test. B: Localization of miR-133a, miR-139-3p, and miR-142-
3p in human bladder samples by in situ hybridization. Scale barZ 100 mm.
Inset: miR-142-3p shows UM cells. Scale bar Z 25 mm. No staining was
observed in a negative control in situ hybridization using the sense strand
of miR-424/503, whereas a strong signal was observed in a positive control
in situ hybridization using U6 in representative cases of normal bladder.
Scale bar Z 100 mm.
Jia et alUM cells compared to B/i cells, whereas miR-142-3p, miR-
199b-5p, and miR-221 were down-regulated in UM cells
compared to B/i cells. Taken together, the RT-qPCR results
conﬁrmed that these ﬁve miRNAs were differentially
expressed between UM and B/i cell populations.
Thenwe veriﬁed the localization of ourmiRNAs of interest
via in situ hybridization. We used LNA oligonucleotide
probes for detection of the miRNAs of interest in human and1176mouse bladders. A positive control using U6 gave strong
signals in human urothelium, whereas no signal was detected
using a nonspeciﬁc probe for themiR-424/503 cluster. Robust
in situ hybridization conditions were established for 3 of 5
miRNAs. Expression of miR-133a and miR-139-3p was
observed in UM cells, whereas miR-142-3p expression was
localized to B/i cells with low expression in UM cells
(Figure 3B). To further validate the phenotypes described for
human urothelial tissues, we extended the study to the anal-
ysis of mouse urothelium. We observed that the miRNA
phenotypes of both human and murine bladder samples were
consistent (Supplemental Figure S2).
CIS Samples Express UM But Not B/i Urothelium-
Speciﬁc Protein Markers
To further explore whether CIS samples were more closely
related to UM cells than B/i cells, as suggested by the miRNA
microarray results, we examined the expression of miRNAs
speciﬁc to UM cells in CIS. Compared to B/i cells, expression
of the ﬁvemiRNAs (Table 2) by RT-qPCR in six independent
CIS biopsies were similar to that of UM cells. miR-133a and
miR-139-3p were upregulated in CIS compared to B/i,
whereas miR-142-3p, miR-199b-5p, and miR-221 were
down-regulated in CIS compared to B/i (Figure 4A).
BecausemiRNAexpression revealed a correlation between
CIS and UM cells, we decided to assess the expression of
several well-established differentiation biomarkers of the
urothelium in a cohort of CIS lesions. We have previously
reported B/i cells to be positive for high molecular weight
cytokeratins, whereas UM cells are characterized by low
molecular weight cytokeratins and UPKII.5,27 Indeed, a high
percentage of CIS lesions revealed a positive UPKII (83.3%)
and CK20 (84.2%) phenotype similar to that of UM cells, as
well as a negative high molecular weight cytokeratins
(10.5%) phenotype (Figure 4, B and C). Table 3 summarizes
the individual immuno-anatomical proﬁles of the 19 CIS
tissue samples.
Discussion
To date, there have not been any studies examining miRNA
expression within normal bladder urothelium and bladder
CIS. Despite a limited number of samples, our study reveals
that the phenotype of CIS most closely resembles that of
UM cells, rather than B/i cells.
A novel approach undertaken in this study is the micro-
anatomical isolation of the normal bladder into three
compartments: i) UM cells, ii) B/i cells, and iii) MP tissue.
Thus far, there is no consensus and there are several incon-
sistencies between different microarray studies for the
majority of miRNAs reported as misexpressed. For instance,
Lin et al24 reported miR-125b and miR-199b to be signiﬁ-
cantly down-regulated in tumors compared to normal tissue,
whereas Veerla et al29 reported high expression of the same
twomiRNAs in invasive (T2/T3) tumors. One explanation forajp.amjpathol.org - The American Journal of Pathology
Figure 4 Phenotypic association of CIS with UM cells by RT-qPCR and immunohistochemistry. A: RT-qPCR results on B/i and CIS samples for various
miRNAs. Graph shows CIS log2 fold expression; CIS expression is normalized to B/i. Horizontal line indicates the sample median. Square indicates the sample
mean. *P < 0.05, **P < 0.005 by Student’s t-test. B: Representative immunohistochemical analyses of UPKII, CK20, and high molecular weight cytokeratins
(HMWCK) in four different CIS tissue samples. Scale barZ 100 mm. C: Quantiﬁcation of the percentage of cases with expression of the respective biomarkers.
Common miR Signature between CIS and UMthis discrepancy is that different populations of normal
bladder tissue were used. It is extremely difﬁcult to obtain
pure urothelium by macrodissection because it often leads to
contamination of the urothelial sample with the lamina
propria. Furthermore, although some groups use normalTable 3 Summary of Immunohistochemical Results in Individual
CIS Tissue Samples
Case No. UPKII CK20 HMWCK
1  þ 
2 þ þ 
3 þ þ 
4 þ þ þ
5 þ þ 
6 þ þ 
7 þ þ 
8 þ  
9   
10 þ þ 
11 þ þ 
12 þ þ 
13  þ 
14 NA þ 
15 þ þ 
16 þ þ þ
17 þ þ 
18 þ þ 
19 þ  
% Positive 83.3 84.2 10.5
NA, core not available.
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the tumor,24,25 which can include nonurothelium components,
such as the muscularis propria. Microdissection is necessary,
therefore, to ensure clean urothelial samples, and it is the only
method to dissect single-layer UM cells.
We proﬁled the expression of 984 human miRNA and
22,277 human mRNA genes in the subpopulations of
normal bladder, CIS tumors, and a normal urothelial cell
line (HUC). Surprisingly, miRNA expression proﬁle
revealed CIS tumors to share a molecular proﬁle displayed
by UM cells, although mRNA expression proﬁle clustered
B/i and UM cells together, but separate from CIS. These
data suggest that gene expression analysis is able to separate
normal from tumor tissues. In fact, more than half of the
differentially expressed genes that were upregulated in CIS,
when compared to normal UM and B/i cells, were associ-
ated with proliferative phenotypes (eg, cell cycle, metabolic
pathways, and pathways in cancer). In contrast, miRNA
expression has been shown to classify tissue samples based
on histogenesis,16 and our data show that CIS samples share
more similarity with UM cells than B/i cells in the normal
urothelium.
There were ﬁve miRNAs that were signiﬁcantly altered
between B/i and UM cells. RT-qPCR and in situ hybrid-
ization conﬁrmed miR-133a and miR-139-3p to be speciﬁc
to UM cells, whereas miR-142-3p was expressed only in B/i
cells. Interestingly, the two UM cell speciﬁc miRNAs, miR-
133a and miR-139-3p, are located on chromosome 18q and
11q, respectively. It is well known that deletions of1177
Jia et alchromosomes 18 and 11 are associated with invasive
bladder carcinomas,30 which mainly arise from high-grade
lesions such as CIS. Conversely, B/i speciﬁc miR-199b-5p
is located on chromosome 9q, the deletion of which is
associated almost exclusively with papillary, nonmuscle
invasive tumors.6,31e33 It is plausible that deletion of these
miRNAs may affect downstream targets involved in bladder
tumorigenesis.
It is well accepted that there are two pathways of bladder
tumor progression.6,34e36 The development of papillary, non-
muscle invasive tumors is largely independent from that of CIS
lesions, as demonstrated through transgenic mouse mod-
els.37e39 Although bladder-speciﬁc expression of mutant
H-RAS led to the growth of papillary tumors,38 simultaneous
deletion of tumor suppressors p53 and Pten gave rise to CIS
with progression to muscle-invasive tumors and metastasis.37
Furthermore, the double inactivation of p53 and Rb through
UPKII-driven expression of SV40T also led to the develop-
ment of high-grade CIS and muscle-invasive tumors.39 A
clonal origin of bladder cancer has been suggested,40 although
the study did not include CIS tumors in the analyses. It remains
unclear, therefore, whether oncogenic changes that give rise to
two phenotypic variants occur within one cell, or whether they
arise in different progenitors (UM versus B/i). Our current
study identiﬁes a strong association between CIS andUMcells
in miRNA expression and the expression of a few well-
established differentiation markers of the UM cell, and
provides evidence of the possible relationship between the two.
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